Comparative Study Between Platelet Rich Plasma and Steroid Injection in Trigger Finger Treatment

Comparative Study Between Intralesional Injection of Platelet Rich Plasma and Intralesional Steroid for the Treatment of Trigger Finger in Black Patients

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06532318

Enrollment

Registered

2024-08-01

Start date

2024-07-24

Completion date

2025-06-23

Last updated

2024-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigger Finger Disorder

Brief summary

The goal of this clinical trial is to learn if platelet rich plasma works to treat early stage trigger finger in adults. It will also learn about the safety platelet rich plasma. The main questions it aims to answer are: Does platelet rich plasma lower the pain associated with trigger finger of participants? Does it improve the hand grip strength and Q DASH score of participants? Researchers will compare platelet rich plasma to Depo-Medrol steroid (a known standard of care for early stage trigger finger) to see if platelet rich plasma works to treat early trigger finger. Participants will: Take platelet rich plasma or a depo-medrol steroid intralesional injection at recruitment into the intervention Visit the clinic once every 4 weeks for checkups and parameter measurements. Investigator will will keep a record of participants progress in symptom remission

Interventions

BIOLOGICALPlatelet rich plasma

Freshly prepared autologus platelet rich plasma

DRUGPfizer Depo-medrol

Methylprednisolone acetate 20mg/ml injection

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Masking description

All participants will have the same assessment and have blood drawn for CBC. Opaque tape masking of the syringes will be done so that care giver and patients are not aware of interventional drug given.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are 18year and above with mild or moderate trigger finger, who are willing to have intra-lesional administration of blood product. No previous treatment for the affected finger.

Exclusion criteria

* Previous steroid injection * Previous Surgery to that finger * Thrombocytopenic patients * Hand and finger contracture * Rheumatoid arthritis of the finger

Design outcomes

Primary

Measure	Time frame	Description
symptom resolution post injection	3 months	reduction of pain using VAS and absence snapping of finger

Secondary

Measure	Time frame	Description
Hand grip strength	3 month	measured grip using hand dynamomter
Q- DASH score	3month	11-item self reported disability questionnaire that consider upper extremity as one functional unit

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026